Phenotype
|
Fish
|
Conditions
|
Figures
|
male organism ratio female organism, abnormal
|
esr2aumo11/umo11
|
standard conditions
|
Fig. 2
from Lu et al., 2017
|
sex determination process quality, abnormal
|
esr2aumo11/umo11
|
standard conditions
|
Fig. 2
from Lu et al., 2017
|
ovary esr2b expression increased amount, abnormal
|
esr2aumo11/umo11
|
standard conditions
|
Fig. 10
from Lu et al., 2017
|
female organism decreased amount, abnormal
|
esr2aumo11/umo11
|
standard conditions
|
Fig. 2
from Lu et al., 2017
|
male organism increased amount, abnormal
|
esr2aumo11/umo11
|
standard conditions
|
Fig. 2
from Lu et al., 2017
|
chorion deformed, abnormal
|
esr2aumo11
|
standard conditions
|
Fig. 8
from Lu et al., 2017
|
hatching premature, abnormal
|
esr2aumo11
|
standard conditions
|
Fig. 8
from Lu et al., 2017
|
ovarian follicle stromal cell hyperplastic, abnormal
|
esr1umo10/umo10; esr2aumo12/umo12
|
standard conditions
|
Fig. 3,
Fig. 5,
Fig. 6,
Fig. 7
from Lu et al., 2017
|
ovarian follicle degenerate, abnormal
|
esr1umo10/umo10; esr2aumo12/umo12
|
standard conditions
|
Fig. 6
from Lu et al., 2017
|
male organism ratio female organism, abnormal
|
esr1umo10/umo10; esr2aumo12/umo12
|
standard conditions
|
Fig. 2
from Lu et al., 2017
|
sex determination process quality, abnormal
|
esr1umo10/umo10; esr2aumo12/umo12
|
standard conditions
|
Fig. 2
from Lu et al., 2017
|
male organism increased amount, abnormal
|
esr1umo10/umo10; esr2aumo12/umo12
|
standard conditions
|
Fig. 2
from Lu et al., 2017
|
female organism decreased amount, abnormal
|
esr1umo10/umo10; esr2aumo12/umo12
|
standard conditions
|
Fig. 2
from Lu et al., 2017
|
chorion deformed, abnormal
|
esr1umo10; esr2aumo12
|
standard conditions
|
Fig. 8
from Lu et al., 2017
|
hatching premature, abnormal
|
esr1umo10; esr2aumo12
|
standard conditions
|
Fig. 8
from Lu et al., 2017
|
ovarian follicle stromal cell hyperplastic, abnormal
|
esr2aumo11/umo11; esr2bumo13/umo13
|
standard conditions
|
Fig. 5,
Fig. 6
from Lu et al., 2017
|
ovarian follicle degenerate, abnormal
|
esr2aumo11/umo11; esr2bumo13/umo13
|
standard conditions
|
Fig. 6
from Lu et al., 2017
|
male organism ratio female organism, abnormal
|
esr2aumo11/umo11; esr2bumo13/umo13
|
standard conditions
|
Fig. 2
from Lu et al., 2017
|
sex determination process quality, abnormal
|
esr2aumo11/umo11; esr2bumo13/umo13
|
standard conditions
|
Fig. 2
from Lu et al., 2017
|
male organism increased amount, abnormal
|
esr2aumo11/umo11; esr2bumo13/umo13
|
standard conditions
|
Fig. 2
from Lu et al., 2017
|
female organism decreased amount, abnormal
|
esr2aumo11/umo11; esr2bumo13/umo13
|
standard conditions
|
Fig. 2
from Lu et al., 2017
|
female organism absent, abnormal
|
esr2aumo11/umo11; esr2bumo13/umo13
|
standard conditions
|
Fig. 7
from Lu et al., 2017
|
ovarian follicle stromal cell hyperplastic, abnormal
|
esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/umo13
|
standard conditions
|
Fig. 5
from Lu et al., 2017
|
male organism ratio female organism, abnormal
|
esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/umo13
|
standard conditions
|
Fig. 2
from Lu et al., 2017
|
sex determination process quality, abnormal
|
esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/umo13
|
standard conditions
|
Fig. 2
from Lu et al., 2017
|
female organism absent, abnormal
|
esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/umo13
|
standard conditions
|
Fig. 6,
Fig. 7
from Lu et al., 2017
|
male organism increased amount, abnormal
|
esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/umo13
|
standard conditions
|
Fig. 2
from Lu et al., 2017
|
female organism decreased amount, abnormal
|
esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/umo13
|
standard conditions
|
Fig. 2
from Lu et al., 2017
|
regulation of female gonad development disrupted, abnormal
|
cyp19a1aumo5/umo5; esr1umo10/+; esr2aumo11/umo11; esr2bumo13/+
|
chemical treatment by environment: bisphenol A
|
Fig. 6
from Song et al., 2019
|
female sex determination decreased occurrence, abnormal
|
cyp19a1aumo5/umo5; esr1umo10/+; esr2aumo11/umo11; esr2bumo13/+
|
chemical treatment by environment: bisphenol A
|
Fig. 6
from Song et al., 2019
|
regulation of female gonad development disrupted, abnormal
|
cyp19a1aumo5/umo5; esr1umo10/+; esr2aumo11/umo11; esr2bumo13/umo13
|
chemical treatment by environment: bisphenol A
|
Fig. 6
from Song et al., 2019
|
female sex determination absent process, abnormal
|
cyp19a1aumo5/umo5; esr1umo10/+; esr2aumo11/umo11; esr2bumo13/umo13
|
chemical treatment by environment: bisphenol A
|
Fig. 6
from Song et al., 2019
|
female sex determination occurrence, ameliorated
|
cyp19a1aumo5/umo5; esr1umo10/umo10; esr2aumo11/+; esr2bumo13/umo13
|
chemical treatment by environment: bisphenol A
|
Fig. 6
from Song et al., 2019
|
regulation of female gonad development normal occurrence, ameliorated
|
cyp19a1aumo5/umo5; esr1umo10/umo10; esr2aumo11/+; esr2bumo13/umo13
|
chemical treatment by environment: bisphenol A
|
Fig. 6
from Song et al., 2019
|
regulation of female gonad development disrupted, abnormal
|
cyp19a1aumo5/umo5; esr1umo10/umo10; esr2aumo11/umo11; esr2bumo13/+
|
chemical treatment by environment: bisphenol A
|
Fig. 6
from Song et al., 2019
|
female sex determination absent process, abnormal
|
cyp19a1aumo5/umo5; esr1umo10/umo10; esr2aumo11/umo11; esr2bumo13/+
|
chemical treatment by environment: bisphenol A
|
Fig. 6
from Song et al., 2019
|
regulation of female gonad development disrupted, abnormal
|
cyp19a1aumo5/umo5; esr1umo10/umo10; esr2aumo11/umo11; esr2bumo13/umo13
|
chemical treatment by environment: bisphenol A
|
Fig. 6
from Song et al., 2019
|
female sex determination absent process, abnormal
|
cyp19a1aumo5/umo5; esr1umo10/umo10; esr2aumo11/umo11; esr2bumo13/umo13
|
chemical treatment by environment: bisphenol A
|
Fig. 6
from Song et al., 2019
|
male organism increased amount, abnormal
|
cyp19a1aumo5/+; dmrt1umo15/+; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/+
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
male organism ratio female organism, abnormal
|
cyp19a1aumo5/+; dmrt1umo15/+; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/+
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
female organism decreased amount, abnormal
|
cyp19a1aumo5/+; dmrt1umo15/+; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/+
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
male organism increased amount, abnormal
|
cyp19a1aumo5/+; dmrt1umo15/+; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/umo13
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
female organism decreased amount, abnormal
|
cyp19a1aumo5/+; dmrt1umo15/+; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/umo13
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
female organism ratio male organism, abnormal
|
cyp19a1aumo5/+; dmrt1umo15/+; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/umo13
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
male organism ratio female organism, abnormal
|
cyp19a1aumo5/+; dmrt1umo15/umo15; esr1umo10/+; esr2aumo12/+; esr2bumo13/umo13
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
male organism decreased amount, abnormal
|
cyp19a1aumo5/+; dmrt1umo15/umo15; esr1umo10/+; esr2aumo12/+; esr2bumo13/umo13
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
female organism increased amount, abnormal
|
cyp19a1aumo5/+; dmrt1umo15/umo15; esr1umo10/+; esr2aumo12/+; esr2bumo13/umo13
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
male organism ratio female organism, abnormal
|
cyp19a1aumo5/+; dmrt1umo15/umo15; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/+
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
male organism decreased amount, abnormal
|
cyp19a1aumo5/+; dmrt1umo15/umo15; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/+
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
female organism increased amount, abnormal
|
cyp19a1aumo5/+; dmrt1umo15/umo15; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/+
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
male organism ratio female organism, abnormal
|
cyp19a1aumo5/+; dmrt1umo15/umo15; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/umo13
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
ovarian follicle degenerate, abnormal
|
cyp19a1aumo5/+; dmrt1umo15/umo15; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/umo13
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
male organism decreased amount, abnormal
|
cyp19a1aumo5/+; dmrt1umo15/umo15; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/umo13
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
female organism increased amount, abnormal
|
cyp19a1aumo5/+; dmrt1umo15/umo15; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/umo13
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
female organism decreased amount, abnormal
|
cyp19a1aumo5/umo5; dmrt1umo15/+; esr1umo10/+; esr2aumo12/+; esr2bumo13/umo13
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
female organism ratio male organism, abnormal
|
cyp19a1aumo5/umo5; dmrt1umo15/+; esr1umo10/+; esr2aumo12/+; esr2bumo13/umo13
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
male organism increased amount, abnormal
|
cyp19a1aumo5/umo5; dmrt1umo15/+; esr1umo10/+; esr2aumo12/+; esr2bumo13/umo13
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
female organism decreased amount, abnormal
|
cyp19a1aumo5/umo5; dmrt1umo15/+; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/+
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
female organism ratio male organism, abnormal
|
cyp19a1aumo5/umo5; dmrt1umo15/+; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/+
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
male organism increased amount, abnormal
|
cyp19a1aumo5/umo5; dmrt1umo15/+; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/+
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
female organism decreased amount, abnormal
|
cyp19a1aumo5/umo5; dmrt1umo15/+; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/umo13
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
female organism ratio male organism, abnormal
|
cyp19a1aumo5/umo5; dmrt1umo15/+; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/umo13
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
male organism increased amount, abnormal
|
cyp19a1aumo5/umo5; dmrt1umo15/+; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/umo13
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
male organism decreased amount, abnormal
|
cyp19a1aumo5/umo5; dmrt1umo15/umo15; esr1umo10/+; esr2aumo12/+; esr2bumo13/+
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
male organism ratio female organism, abnormal
|
cyp19a1aumo5/umo5; dmrt1umo15/umo15; esr1umo10/+; esr2aumo12/+; esr2bumo13/+
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
female organism increased amount, abnormal
|
cyp19a1aumo5/umo5; dmrt1umo15/umo15; esr1umo10/+; esr2aumo12/+; esr2bumo13/+
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
male organism decreased amount, abnormal
|
cyp19a1aumo5/umo5; dmrt1umo15/umo15; esr1umo10/+; esr2aumo12/+; esr2bumo13/umo13
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
male organism ratio female organism, abnormal
|
cyp19a1aumo5/umo5; dmrt1umo15/umo15; esr1umo10/+; esr2aumo12/+; esr2bumo13/umo13
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
female organism increased amount, abnormal
|
cyp19a1aumo5/umo5; dmrt1umo15/umo15; esr1umo10/+; esr2aumo12/+; esr2bumo13/umo13
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
male organism ratio female organism, abnormal
|
cyp19a1aumo5/umo5; dmrt1umo15/umo15; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/+
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
male organism decreased amount, abnormal
|
cyp19a1aumo5/umo5; dmrt1umo15/umo15; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/+
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
female organism increased amount, abnormal
|
cyp19a1aumo5/umo5; dmrt1umo15/umo15; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/+
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
male organism ratio female organism, abnormal
|
cyp19a1aumo5/umo5; dmrt1umo15/umo15; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/umo13
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
ovarian follicle degenerate, abnormal
|
cyp19a1aumo5/umo5; dmrt1umo15/umo15; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/umo13
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
male organism decreased amount, abnormal
|
cyp19a1aumo5/umo5; dmrt1umo15/umo15; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/umo13
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|
female organism increased amount, abnormal
|
cyp19a1aumo5/umo5; dmrt1umo15/umo15; esr1umo10/umo10; esr2aumo12/umo12; esr2bumo13/umo13
|
standard conditions
|
Fig. 4
from Wu et al., 2020
|